Elevai Labs (ELAB) said Thursday that its Elevai Biosciences subsidiary filed two patent applications for its lead candidate, EL-22, to treat muscle loss in obese patients.
The applications cover both standalone and combination therapies with GLP-1 receptor agonists, according to the company.
A phase 1 study of EL-22 in South Korea has been completed, showing safety and tolerability in healthy volunteers, Elevai said, adding it plans to evaluate the investigational drug's efficacy in combination with GLP-1 to counteract muscle wasting associated with the medications while promoting weight loss.
Shares of the drug developer rose more than 30% in recent premarket activity.
Price: 0.1109, Change: +0.03, Percent Change: +30.16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.